Eskandar Taghizadeh, Forough Taheri, Pedram G. Renani, Željko Reiner, Jamshid G. Navashenaq and Amirhossein Sahebkar* Pages 3165 - 3174 ( 10 )
Background: Atherosclerosis is a chronic inflammatory disease and a leading cause of coronary artery disease, peripheral vascular disease and stroke. Lipid-laden macrophages are derived from circulating monocytes and form fatty streaks as the first step of atherogenesis.
Methods: An electronic search in major databases was performed to review new therapeutic opportunities for influencing the inflammatory component of atherosclerosis based on monocytes/macrophages targeting.
Results: In the past two decades, macrophages have been recognized as the main players in atherogenesis but also in its thrombotic complications. There is a growing interest in immunometabolism and recent studies on metabolism of macrophages have created new therapeutic options to treat atherosclerosis. Targeting recruitment, polarization, cytokine profile extracellular matrix remodeling, cholesterol metabolism, oxidative stress, inflammatory activity and non-coding RNAs of monocyte/macrophage have been proposed as potential therapeutic approaches against atherosclerosis.
Conclusion: Monocytes/macrophages have a crucial role in progression and pathogenesis of atherosclerosis. Therefore, targeting monocyte/macrophage therapy in order to achieve anti-inflammatory effects might be a good option for prevention of atherosclerosis.
Leukocyte, atherosclerosis, vascular inflammation, immune system, anti-inflammatory, monocyte/macrophage.
Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Sharekord Branch, Islamic Azad University, Sharekord, Sharekord Branch, Islamic Azad University, Sharekord, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Department of Internal Medicine, Zagreb, Immunogenetic and Cell Culture Department, Immunology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Halal Research Center of IRI, FDA, Tehran